Abstract
Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic im......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
